Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.

Two Palestinian pediatric cancer patients arrived in the U.S. for treatment in Washington this week, but renewed fighting in ...

Over 60% of prescriptions for conditions like hypertension and mental health disorders in the US rely on Indian-made drugs, ...

After Trump threatened 25% tariffs on pharma imports, J&J became the latest pharma company to announce investments in the U.S.

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease ...

Johnson & Johnson has laid out plans to raise U.S. investments by 25% to more than $55 billion over the next four years, as a ...

Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major ...

Johnson & Johnson plans to spend more than $55 billion to build four plants in the U.S. over the next four years, it said on ...

Scientists in the US who do research on mRNA technology worry their funding may be cut under President Trump. mRNA technology is the basis for COVID- and other vaccines and could play a role in cancer ...

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...